ReviewInternational journal of nanomedicine2013
The physiology of cardiovascular disease and innovative liposomal platforms for therapy.
Review in International journal of nanomedicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Injectable Self-Oxygenating Cardio-Protective and Tissue Adhesive Silk-Based Hydrogel for Alleviating Ischemia After Mi Injury.Small (Weinheim an der Bergstrasse, Germany) · 2024Article
- Intranasal Delivery of Carvedilol- and Quercetin-Encapsulated Cationic Nanoliposomes for Cardiovascular Targeting: Formulation andACS applied bio materials · 2024Article
- Improving Photodynamic Therapy Anticancer Activity of a Mitochondria-Targeted Coumarin Photosensitizer Using a Polyurethane-Polyurea Hybrid Nanocarrier.Biomacromolecules · 2022Article
- Nanoparticles Targeting the Molecular Pathways of Heart Remodeling and Regeneration.Pharmaceutics · 2022Review
- High-Frequency Ultrasound Assessment of Skin and Oral Mucosa in Metabolic Syndrome Patients-A Cross-Sectional Study.Journal of clinical medicine · 2021Article
- Nanoparticle-Mediated Drug Delivery for the Treatment of Cardiovascular Diseases.International journal of nanomedicine · 2020Review
- Photoactive Liposomal Formulation of PVP-Conjugated Chlorin e6 for Photodynamic Reduction of Atherosclerotic Plaque.International journal of molecular sciences · 2019Article
- Nuclear imaging of liposomal drug delivery systems: A critical review of radiolabelling methods and applications in nanomedicine.Advanced drug delivery reviews · 2019Review
- Mitochondria-targeted cyclosporin A delivery system to treat myocardial ischemia reperfusion injury of rats.Journal of nanobiotechnology · 2019Article
- Size-Dependent Ability of Liposomes to Accumulate in the Ischemic Myocardium and Protect the Heart.Journal of cardiovascular pharmacology · 2018Article
- Monocyte-mediated drug delivery systems for the treatment of cardiovascular diseases.Drug delivery and translational research · 2018Review
- Cardiovascular Bio-Engineering: Current State of the Art.Journal of cardiovascular translational research · 2017Review
- Nanomedicine applied to cardiovascular diseases: latest developments.Therapeutic advances in cardiovascular disease · 2017Review
- A specifically designed nanoconstruct associates, internalizes, traffics in cardiovascular cells, and accumulates in failing myocardium: a new strategy for heart failure diagnostics and therapeutics.European journal of heart failure · 2016Article
- Nanomedicine as a strategy to fight thrombotic diseases.Future science OA · 2015Review
- Intrapericardial administration of mesenchymal stem cells in a large animal model: a bio-distribution analysis.PloS one · 2015Article
- Organ-on-a-chip platforms for studying drug delivery systems.Journal of controlled release : official journal of the Controlled Release Society · 2014Review
- Manganese ferrite-based nanoparticles induce ex vivo, but not in vivo, cardiovascular effects.International journal of nanomedicine · 2014Article
- Enhanced incorporation of docosahexaenoic acid in serum, heart, and brain of rats given microemulsions of fish oil.Molecular and cellular biochemistry · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart disease remains the major cause of death in males and females, emphasizing the need for novel strategies to improve patient treatment and survival. A therapeutic approach, still in its infancy, is the development of site-specific drug-delivery systems. Nanoparticle-based delivery systems, such as liposomes, have evolved into robust platforms for site-specific delivery of therapeutics. In this review, the clinical impact of cardiovascular disease and the pathophysiology of different subsets of the disease are described. Potential pathological targets for therapy are introduced, and promising advances in nanotherapeutic cardiovascular applications involving liposomal platforms are presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.